|
|
Volumn 26, Issue 10, 2013, Pages 561-569
|
|
A new platform for constructing antibody-cytokine fusion proteins (immunocytokines) with improved biological properties and adaptable cytokine activity
|
|
Author keywords
immunocytokine; interleukin 2; receptor specificity
|
|
Indexed keywords
ANTI-TUMOR ACTIVITIES;
BIOLOGICAL PROPERTIES;
COMPLEMENT-DEPENDENT CYTOTOXICITIES;
CYTOTOXIC ACTIVITIES;
IMMUNOCYTOKINE;
INTERLEUKIN-2;
RECEPTOR SPECIFICITY;
TRANSFECTED CELLS;
CHAINS;
CYTOTOXICITY;
MOLECULES;
ANTIBODIES;
ANTINEOPLASTIC AGENT;
HYBRID PROTEIN;
INTERLEUKIN 2;
INTERLEUKIN 2 RECEPTOR;
ANIMAL CELL;
ANIMAL EXPERIMENT;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
BINDING AFFINITY;
CONTROLLED STUDY;
DRUG BINDING;
DRUG BLOOD LEVEL;
DRUG CYTOTOXICITY;
DRUG HALF LIFE;
DRUG SPECIFICITY;
DRUG UPTAKE;
FEMALE;
HUMAN;
HUMAN CELL;
MOUSE;
NONHUMAN;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
IMMUNOCYTOKINE;
INTERLEUKIN 2;
RECEPTOR SPECIFICITY;
AMINO ACID SEQUENCE;
ANIMALS;
ANTIBODIES;
CELL LINE;
CYTOKINES;
FEMALE;
GLYCOSYLATION;
HUMANS;
MICE;
MOLECULAR SEQUENCE DATA;
PROTEIN ENGINEERING;
RECEPTORS, INTERLEUKIN-2;
RECOMBINANT FUSION PROTEINS;
SUBSTRATE SPECIFICITY;
|
|
EID: 84884998926
PISSN: 17410126
EISSN: 17410134
Source Type: Journal
DOI: 10.1093/protein/gzt045 Document Type: Article |
|
Times cited : (31)
|
|
References (17)
|
